Ipca Laboratories Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/an6oz1epk8q96zcsg0k6n173.pdf

Key Takeaways


Margin Walk: The Q1 Reset

Jain: "So, EBIDTA from our last financial year, it's going down by almost around 2.25%. It's not 1%, 1% is from earlier guidelines."

UK Business: A Distributor Breakup and a Slow Rebuild

Jain: "It was only because of payments not coming in time, we have said that we will not be able to do business and then, we will start our own distribution in the UK."

Domestic Formulations: Strong Underlying Growth, Masked by Base Effects

Jain: "Our market shares are increasing, most therapies are doing well. So, it's the right time for us to increase our overall penetration in India and that's why this step is taken."

Field Force Investment: Paying Now, Earning Later

Jain: "Normally, a rep takes two years' time to become productive. That's what our past experience is there. Productive means, I would say that he starts recovering his cost, his supervision costs all the promotional costs we incur on them, and then he starts contributing towards the margin."

API Business: Losartan Disruption and a Long-Term Bet


Export Markets: Russia Recovers, Sri Lanka Slips, US Waits

Jain: "My disclaimer is that nobody's waiting for me. So, I had to go and disturb the market and create the market again."

Guidance & Commitments

CommitmentSpecificsTimeline
Overall sales growth9-10% (revised down from 10-11%)FY23
Domestic formulations growth~12-13% (ex-anti-malarial: 17-20%)FY23
Export formulations growth13-15%FY23
Export generic growth~5%FY23
Institutional anti-malarial exportDecline ~8-10%FY23
API business growth~5%FY23
EBITDA margin~21% (revised down from ~22%)FY23
EBITDA margin recovery~23% "reasonably possible"FY24
UK business recoveryRecover ~80-85% of prior businessFY23
Field force expansionAdd ~1,200 MRs (800 already recruited)FY23
New MR productivityBreakeven and margin-contributingWithin ~2 years
API business aspirationReach ~₹2,000 crores3-4 years
Dewas plant commercial contributionFirst business from India and data-submission marketsFY24
Effective tax rate~27.5% to 28%FY23 and future years

Key Metrics

MetricQ1 FY23
Revenue₹685 cr domestic formulations, +12% YoY from ₹613 cr
Domestic formulations growth ex-antimalarial+17% YoY
Export formulations growth+14% YoY
Export generics revenue₹213 cr, -2% YoY from ₹217 cr
Institutional anti-malarial export revenue₹97 cr, -17% YoY from ₹116 cr
API business growth-10% YoY
EBITDA margin (standalone)19.5%, down from 27.1% in Q1 FY22
EBITDA margin (adjusted for other income)17.9% (per an analyst's math)
Material cost to total income34.71%, up 1.33 ppt from 33.39% in Q1 FY22
Deferred tax provision increase₹8.76 cr charged to P&L
Domestic market share1.85%
Field force size~6,000 sanctioned reps by year-end, ~800 of 1,200 planned additions already recruited
Metro cities growth (Delhi, Mumbai, etc.)+23% YoY in Q1
Pain management growth+20% YoY in Q1
FY23 EBITDA margin guidance~21%, revised from ~22% earlier and 23.25% in FY22
FY23 overall sales growth guidance9–10%, revised from 10–11%
FY23 domestic formulations growth guidance12–13%
FY23 effective tax rate guidance~27.5%